Symbols / VTYX
VTYX Chart
About
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in Phase 2a trial for patients with early Parkinson's disease and is in Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.00B |
| Enterprise Value | 813.55M | Income | -106.61M | Sales | — |
| Book/sh | 2.68 | Cash/sh | 2.70 | Dividend Yield | — |
| Payout | 0.00% | Employees | 83 | IPO | — |
| P/E | — | Forward P/E | -8.57 | PEG | — |
| P/S | — | P/B | 5.20 | P/C | — |
| EV/EBITDA | -6.99 | EV/Sales | — | Quick Ratio | 17.15 |
| Current Ratio | 17.86 | Debt/Eq | 5.24 | LT Debt/Eq | — |
| EPS (ttm) | -1.49 | EPS next Y | -1.63 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-02-26 | ROA | -28.46% |
| ROE | -45.35% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 71.75M |
| Shs Float | 47.85M | Short Float | 6.66% | Short Ratio | 0.78 |
| Short Interest | — | 52W High | 25.00 | 52W Low | 0.78 |
| Beta | 1.26 | Avg Volume | 3.35M | Volume | 1.08M |
| Target Price | $13.29 | Recom | None | Prev Close | $13.95 |
| Price | $13.96 | Change | 0.07% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$13.29
Mean price target
2. Current target
$13.96
Latest analyst target
3. DCF / Fair value
$-11.91
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$13.96
Low
$9.00
High
$14.00
Mean
$13.29
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-08 | down | Oppenheimer | Outperform → Perform | — |
| 2026-01-08 | down | Wells Fargo | Overweight → Equal-Weight | $14 |
| 2026-01-08 | down | HC Wainwright & Co. | Buy → Neutral | $14 |
| 2026-01-08 | down | UBS | Buy → Neutral | $14 |
| 2026-01-08 | down | LifeSci Capital | Outperform → Market Perform | $14 |
| 2026-01-08 | down | Canaccord Genuity | Buy → Hold | $14 |
| 2026-01-07 | init | UBS | — → Buy | $20 |
| 2025-11-07 | main | Canaccord Genuity | Buy → Buy | $16 |
| 2025-11-07 | main | Wells Fargo | Overweight → Overweight | $14 |
| 2025-11-05 | up | HC Wainwright & Co. | Neutral → Buy | $18 |
| 2025-10-27 | main | Oppenheimer | Outperform → Outperform | $14 |
| 2025-10-01 | init | Clear Street | — → Buy | $11 |
| 2025-01-14 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-11-11 | reit | HC Wainwright & Co. | Neutral → Neutral | $6 |
| 2024-11-08 | reit | Oppenheimer | Outperform → Outperform | $9 |
| 2024-10-15 | reit | HC Wainwright & Co. | Neutral → Neutral | $6 |
| 2024-09-23 | reit | HC Wainwright & Co. | Neutral → Neutral | $6 |
| 2024-08-12 | main | Wells Fargo | Overweight → Overweight | $11 |
| 2024-08-12 | main | Canaccord Genuity | Buy → Buy | $14 |
| 2024-07-30 | reit | HC Wainwright & Co. | Neutral → Neutral | $6 |
- Ventyx Biosciences agrees to $14.00 cash per share merger with Eli Lilly; HSR waiting period cleared - TradingView Mon, 23 Feb 2026 21
- VTYX Stock Skyrockets 156% in a Month: Here's What You Need to Know - November 18, 2025 - Zacks Investment Research ue, 18 Nov 2025 08
- GLAZER CAPITAL, LLC Acquires Significant Stake in Ventyx Biosciences Inc - GuruFocus Wed, 25 Feb 2026 00
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc. - VTYX - PR Newswire hu, 15 Jan 2026 08
- Ventyx Biosciences (VTYX) Outlook Strengthened by Cost Optimization and Positive Clinical Data - Yahoo Finance Sun, 23 Nov 2025 08
- VTYX Surges On Phase 2 Data: VTX3232 Cuts Inflammation, Lifts Stock By 83% After Hours - Nasdaq hu, 23 Oct 2025 07
- Ventyx Biosciences (Nasdaq: VTYX) schedules Jefferies London fireside chat on Nov. 19 - Stock Titan Mon, 17 Nov 2025 08
- Ventyx BiosciencVentyx Biosciences Stock Jumps 56% After Hours On Reports Of $1 Billion Eli Lilly Buyout - Stocktwits ue, 06 Jan 2026 08
- Ventyx Biosciences stock surges after Eli Lilly acquisition talks - Investing.com ue, 06 Jan 2026 08
- Small Biotech Launches On Rumored $1 Billion Eli Lilly Buyout - Investor's Business Daily ue, 06 Jan 2026 08
- $VTYX stock is up 48% today. Here's what we see in our data. - Quiver Quantitative Wed, 07 Jan 2026 08
- Ventyx up on mid-stage trial data for heart drug (VTYX:NASDAQ) - Seeking Alpha hu, 23 Oct 2025 07
- With 57% ownership, Ventyx Biosciences, Inc. (NASDAQ:VTYX) boasts of strong institutional backing - Yahoo Finance Mon, 24 Nov 2025 08
- Ventyx (Nasdaq: VTYX) expands VTX2735 Phase 2 RP study, interim data now Q1 2026 - Stock Titan ue, 02 Dec 2025 08
- Ventyx stock soars after positive Phase 2 results for inflammation drug - Investing.com Wed, 22 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 47345 | 365461.0 | — | Sale at price 7.72 per share. | MOHAN RAJU | Chief Executive Officer | — | 2025-12-18 00:00:00 | D |
| 1 | 12675 | 97840.0 | — | Sale at price 7.72 per share. | NUSS JOHN M. PH.D. | Officer | — | 2025-12-18 00:00:00 | D |
| 2 | 116668 | nan | — | — | MOHAN RAJU | Chief Executive Officer | — | 2025-12-17 00:00:00 | D |
| 3 | 34930 | nan | — | — | NUSS JOHN M. PH.D. | Officer | — | 2025-12-17 00:00:00 | D |
| 4 | 3000 | 28500.0 | — | Stock Award(Grant) at price 9.50 per share. | FORMAN MARK S M.D., PH.D. | Officer | — | 2025-11-17 00:00:00 | D |
| 5 | 1767 | 16786.0 | — | Stock Award(Grant) at price 9.50 per share. | GONZALES ROY M. | Officer | — | 2025-11-17 00:00:00 | D |
| 6 | 3000 | 3090.0 | — | Stock Award(Grant) at price 1.03 per share. | FORMAN MARK S M.D., PH.D. | Officer | — | 2025-05-15 00:00:00 | D |
| 7 | 1750 | 1802.0 | — | Stock Award(Grant) at price 1.03 per share. | GONZALES ROY M. | Officer | — | 2025-05-15 00:00:00 | D |
| 8 | 1887 | 2019.0 | — | Sale at price 1.07 per share. | NUSS JOHN M. PH.D. | Officer | — | 2025-04-02 00:00:00 | D |
| 9 | 11844 | nan | — | — | MOHAN RAJU | Chief Executive Officer | — | 2025-03-28 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -147.10M | -207.05M | -112.67M | -72.57M |
| TotalUnusualItems | -11.05M | |||
| TotalUnusualItemsExcludingGoodwill | -11.05M | |||
| NetIncomeFromContinuingOperationNetMinorityInterest | -135.12M | -192.96M | -108.43M | -83.75M |
| ReconciledDepreciation | 1.35M | 941.00K | 470.00K | 30.00K |
| EBITDA | -147.10M | -207.05M | -112.67M | -83.62M |
| EBIT | -148.45M | -207.99M | -113.14M | -83.65M |
| NetInterestIncome | 13.42M | 15.07M | 4.67M | -21.00K |
| InterestExpense | 0.00 | 99.00K | ||
| InterestIncome | 13.42M | 15.07M | 4.67M | 78.00K |
| NormalizedIncome | -135.12M | -192.96M | -108.43M | -72.69M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -135.12M | -192.96M | -108.43M | -83.75M |
| TotalExpenses | 148.45M | 207.99M | 113.14M | 67.15M |
| TotalOperatingIncomeAsReported | -148.45M | -207.99M | -113.14M | -67.15M |
| DilutedAverageShares | 68.48M | 58.54M | 52.47M | 12.83M |
| BasicAverageShares | 68.48M | 58.54M | 52.47M | 12.83M |
| DilutedEPS | -1.97 | -3.30 | -2.07 | -6.65 |
| BasicEPS | -1.97 | -3.30 | -2.07 | -6.65 |
| DilutedNIAvailtoComStockholders | -135.12M | -192.96M | -108.43M | -85.30M |
| NetIncomeCommonStockholders | -135.12M | -192.96M | -108.43M | -85.30M |
| PreferredStockDividends | 1.55M | |||
| NetIncome | -135.12M | -192.96M | -108.43M | -83.75M |
| NetIncomeIncludingNoncontrollingInterests | -135.12M | -192.96M | -108.43M | -83.75M |
| NetIncomeContinuousOperations | -135.12M | -192.96M | -108.43M | -83.75M |
| PretaxIncome | -135.12M | -192.96M | -108.43M | -83.75M |
| OtherIncomeExpense | -88.00K | -42.00K | 41.00K | -16.58M |
| OtherNonOperatingIncomeExpenses | -88.00K | -42.00K | 41.00K | -5.53M |
| GainOnSaleOfSecurity | -11.05M | |||
| NetNonOperatingInterestIncomeExpense | 13.42M | 15.07M | 4.67M | -21.00K |
| InterestExpenseNonOperating | 0.00 | 99.00K | ||
| InterestIncomeNonOperating | 13.42M | 15.07M | 4.67M | 78.00K |
| OperatingIncome | -148.45M | -207.99M | -113.14M | -67.15M |
| OperatingExpense | 148.45M | 207.99M | 113.14M | 67.15M |
| ResearchAndDevelopment | 117.00M | 175.77M | 87.74M | 58.48M |
| SellingGeneralAndAdministration | 31.45M | 32.23M | 25.40M | 8.67M |
| GeneralAndAdministrativeExpense | 31.45M | 32.23M | 25.40M | 8.67M |
| OtherGandA | 31.45M | 32.23M | 25.40M | 8.67M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 71.13M | 59.24M | 56.98M | 50.41M |
| ShareIssued | 71.13M | 59.24M | 56.98M | 50.41M |
| TotalDebt | 10.79M | 12.51M | 1.56M | 0.00 |
| TangibleBookValue | 254.04M | 243.92M | 353.89M | 279.20M |
| InvestedCapital | 254.04M | 243.92M | 353.89M | 279.20M |
| WorkingCapital | 216.85M | 242.08M | 314.33M | 250.74M |
| NetTangibleAssets | 254.04M | 243.92M | 353.89M | 279.20M |
| CapitalLeaseObligations | 10.79M | 12.51M | 1.56M | 0.00 |
| CommonStockEquity | 254.04M | 243.92M | 353.89M | 279.20M |
| TotalCapitalization | 254.04M | 243.92M | 353.89M | 279.20M |
| TotalEquityGrossMinorityInterest | 254.04M | 243.92M | 353.89M | 279.20M |
| StockholdersEquity | 254.04M | 243.92M | 353.89M | 279.20M |
| GainsLossesNotAffectingRetainedEarnings | 157.00K | -50.00K | -1.12M | -58.00K |
| OtherEquityAdjustments | 157.00K | -50.00K | -1.12M | -58.00K |
| RetainedEarnings | -554.31M | -419.19M | -226.22M | -117.80M |
| AdditionalPaidInCapital | 808.19M | 663.15M | 581.24M | 397.05M |
| CapitalStock | 7.00K | 6.00K | 6.00K | 5.00K |
| CommonStock | 7.00K | 6.00K | 6.00K | 5.00K |
| PreferredStock | 0.00 | 0.00 | ||
| TotalLiabilitiesNetMinorityInterest | 22.52M | 33.77M | 17.50M | 12.28M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 9.74M | 11.51M | 1.15M | 0.00 |
| DerivativeProductLiabilities | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 9.74M | 11.51M | 1.15M | 0.00 |
| LongTermCapitalLeaseObligation | 9.74M | 11.51M | 1.15M | 0.00 |
| CurrentLiabilities | 12.78M | 22.27M | 16.36M | 12.28M |
| CurrentDebtAndCapitalLeaseObligation | 1.05M | 1.00M | 412.00K | |
| CurrentCapitalLeaseObligation | 1.05M | 1.00M | 412.00K | 0.00 |
| PayablesAndAccruedExpenses | 11.72M | 21.26M | 15.95M | 12.28M |
| CurrentAccruedExpenses | 8.59M | 15.51M | 9.51M | 7.62M |
| Payables | 3.13M | 5.76M | 6.43M | 4.66M |
| AccountsPayable | 3.13M | 5.76M | 6.43M | 4.66M |
| TotalAssets | 276.56M | 277.69M | 371.40M | 291.48M |
| TotalNonCurrentAssets | 46.94M | 13.35M | 40.71M | 28.46M |
| OtherNonCurrentAssets | 1.03M | 1.08M | 96.00K | 60.00K |
| InvestmentsAndAdvances | 35.62M | 0.00 | 38.67M | 28.15M |
| OtherInvestments | 28.15M | |||
| InvestmentinFinancialAssets | 35.62M | 0.00 | 38.67M | 28.15M |
| AvailableForSaleSecurities | 35.62M | 38.67M | 28.15M | |
| NetPPE | 10.28M | 12.27M | 1.94M | 254.00K |
| AccumulatedDepreciation | -470.00K | -259.00K | -95.00K | -24.00K |
| GrossPPE | 10.75M | 12.53M | 2.04M | 278.00K |
| Leases | 283.00K | 0.00 | ||
| ConstructionInProgress | 15.00K | 157.00K | 0.00 | |
| OtherProperties | 9.81M | 11.69M | 1.68M | 134.00K |
| MachineryFurnitureEquipment | 641.00K | 686.00K | 360.00K | 144.00K |
| Properties | 0.00 | 0.00 | ||
| CurrentAssets | 229.62M | 264.35M | 330.69M | 263.02M |
| OtherCurrentAssets | 12.30M | 12.12M | 12.75M | 4.44M |
| PrepaidAssets | 4.44M | |||
| CashCashEquivalentsAndShortTermInvestments | 217.32M | 252.22M | 317.94M | 258.58M |
| OtherShortTermInvestments | 190.06M | 200.64M | 253.12M | 187.78M |
| CashAndCashEquivalents | 27.26M | 51.58M | 64.82M | 70.79M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -131.11M | -167.04M | -99.05M | -38.91M |
| IssuanceOfDebt | 0.00 | 450.00K | ||
| IssuanceOfCapitalStock | 121.65M | 48.41M | 165.40M | 323.04M |
| CapitalExpenditure | -241.00K | -514.00K | -275.00K | -262.00K |
| IncomeTaxPaidSupplementalData | 3.00K | |||
| EndCashPosition | 28.23M | 52.55M | 64.82M | 70.79M |
| BeginningCashPosition | 52.55M | 64.82M | 70.79M | 244.00K |
| EffectOfExchangeRateChanges | -55.00K | -12.00K | -42.00K | 11.00K |
| ChangesInCash | -24.26M | -12.25M | -5.93M | 70.54M |
| FinancingCashFlow | 122.11M | 53.33M | 167.77M | 323.55M |
| CashFlowFromContinuingFinancingActivities | 122.11M | 53.33M | 167.77M | 323.55M |
| ProceedsFromStockOptionExercised | 466.00K | 4.92M | 2.37M | 65.00K |
| NetPreferredStockIssuance | 26.60M | 0.00 | 0.00 | 164.22M |
| PreferredStockIssuance | 26.60M | 0.00 | 0.00 | 164.22M |
| NetCommonStockIssuance | 95.05M | 48.41M | 165.40M | 158.81M |
| CommonStockIssuance | 95.05M | 48.41M | 165.40M | 158.81M |
| NetIssuancePaymentsOfDebt | 0.00 | 450.00K | ||
| NetLongTermDebtIssuance | 0.00 | 450.00K | ||
| LongTermDebtIssuance | 0.00 | 450.00K | ||
| InvestingCashFlow | -15.51M | 100.94M | -74.93M | -214.37M |
| CashFlowFromContinuingInvestingActivities | -15.51M | 100.94M | -74.93M | -214.37M |
| NetInvestmentPurchaseAndSale | -15.27M | 101.45M | -74.66M | -216.00M |
| SaleOfInvestment | 268.38M | 373.73M | 272.58M | 16.50M |
| PurchaseOfInvestment | -283.65M | -272.27M | -347.24M | -232.50M |
| NetBusinessPurchaseAndSale | 0.00 | 1.90M | ||
| SaleOfBusiness | 0.00 | 1.90M | ||
| NetPPEPurchaseAndSale | -241.00K | -514.00K | -275.00K | -262.00K |
| PurchaseOfPPE | -241.00K | -514.00K | -275.00K | -262.00K |
| OperatingCashFlow | -130.87M | -166.52M | -98.77M | -38.65M |
| CashFlowFromContinuingOperatingActivities | -130.87M | -166.52M | -98.77M | -38.65M |
| ChangeInWorkingCapital | -10.56M | 5.81M | -5.16M | 4.02M |
| ChangeInOtherCurrentLiabilities | -847.00K | -59.00K | -326.00K | 0.00 |
| ChangeInPayablesAndAccruedExpense | -9.56M | 5.25M | 3.50M | 8.40M |
| ChangeInAccruedExpense | -6.91M | 5.99M | 1.89M | 5.96M |
| ChangeInPayable | -2.64M | -745.00K | 1.61M | 2.44M |
| ChangeInAccountPayable | -2.64M | -745.00K | 1.61M | 2.44M |
| ChangeInPrepaidAssets | -159.00K | 616.00K | -8.34M | -4.39M |
| OtherNonCashItems | -88.00K | 27.27M | ||
| StockBasedCompensation | 22.93M | 28.59M | 16.57M | 2.73M |
| AssetImpairmentCharge | 0.00 | 285.00K | 0.00 | |
| AmortizationOfSecurities | -9.52M | -9.18M | -2.23M | 0.00 |
| DepreciationAmortizationDepletion | 1.35M | 941.00K | 470.00K | 30.00K |
| DepreciationAndAmortization | 1.35M | 941.00K | 470.00K | 30.00K |
| Depreciation | 1.35M | 941.00K | 470.00K | 30.00K |
| OperatingGainsLosses | 136.00K | 11.05M | ||
| GainLossOnInvestmentSecurities | 11.05M | |||
| GainLossOnSaleOfPPE | 136.00K | 0.00 | ||
| NetIncomeFromContinuingOperations | -135.12M | -192.96M | -108.43M | -83.75M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for VTYX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|